CASGEVY® (exagamglogene autotemcel) | Patient Website
CASGEVY is a one-time therapy used to treat people aged 12 years and older with: sickle cell disease (SCD) who have frequent vaso-occlusive crises or VOCs. beta thalassemia (β-thalassemia) who need regular blood transfusions
Exagamglogene autotemcel - Wikipedia
Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease [3] [5] and transfusion-dependent beta thalassemia. [3] It was developed by Vertex Pharmaceuticals and CRISPR Therapeutics. [9]
Casgevy: Uses, Dosage, Side Effects, Warnings - Drugs.com
Jan 17, 2024 · Casgevy (exagamglogene autotemcel) is a gene therapy that is given as a one-time intravenous infusion to treat adults and children aged 12 years and older with: Sickle cell disease with recurrent vaso-occlusive crises (VOCs). …
FDA Approves First Gene Therapies to Treat Patients with Sickle …
Casgevy, a cell-based gene therapy, is approved for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises. Casgevy is the first...
CASGEVY | FDA - U.S. Food and Drug Administration
CASGEVY indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso occlusive crises (VOCs).
HCP Official Website for CASGEVY® (exagamglogene autotemcel)
CASGEVY is indicated for the treatment of patients aged 12 years and older with: sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) transfusion-dependent β-thalassemia (TDT)
Casgevy - European Medicines Agency (EMA)
Dec 15, 2023 · Casgevy is a medicine used to treat blood disorders known as beta thalassaemia and sickle cell disease in patients 12 years and older. For beta thalassaemia, Casgevy is used in patients who require regular blood transfusions.
Patient Information | CASGEVY® (exagamglogene autotemcel)
CASGEVY is a one-time* gene therapy that may help people 12 years and older with sickle cell disease (SCD) and frequent vaso-occlusive crises (VOCs) live severe VOC-free. CASGEVY uses your own blood stem cells to help your body make working red …
Therapies | CRISPR Therapeutics
CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, is approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia.
The world's 1st CRISPR therapy has been approved. Here's …
Jan 18, 2024 · Exa-cel, also known by its brand name Casgevy, received its first regulatory approval on Nov. 16, 2023 from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to treat two...
- Some results have been removed